Accessibility Menu
Jw (Cayman) Therapeutics logo

Jw (Cayman) Therapeutics(OTC) JWCTF

Market Cap$82.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 Year-91%
1 Year-69%
1 Month-13%
$0.20
-4.40%
-0.01Today
Jw (Cayman) Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.202026-08-06
Jw (Cayman) Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.202026-07-13
1 month-13.25%USD 0.232026-07-06
3 month-27.8%USD 0.282026-04-17
Year to date-43.83%USD 0.362025-12-22
1 year-69.37%USD 0.662025-08-05
3 year-36.35%USD 0.322023-08-07
5 year-90.81%USD 2.202021-07-28
Since inception-92.9%USD 2.852021-07-15

Jw (Cayman) Therapeutics Financials at a Glance

Market Cap

$82.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥438.93M

Net Income (TTM)

-CN¥1.14B

EPS (TTM)

-$0.19

P/E Ratio

-1.07

Dividend

$0.00

Beta (Volatility)

169.48 (High)

Price

$0.20

Volume

680,000

Open

$0.20

Previous Close

$0.20

Daily Range

$0.20 - $0.20

52-Week Range

$0.20 - $0.66

Estimated Earnings Date

Aug 27, 2026

JWCTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jw (Cayman) Therapeutics

JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical company focused on developing advanced cell-based immunotherapeutic solutions for hematological cancers and solid tumors. The company specializes in innovative treatments, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, leveraging patients' immune cells to combat cancer.

Products and Services
  • Carteyva (relmacabtagene autoleucel) for blood cancer treatment
  • JWCAR129, an autologous CAR-T therapy for multiple myeloma
  • JWATM204 and JWATM203, T-cell receptor therapies targeting hepatocellular carcinoma
Growth Outlook
  • Strong pipeline with multiple CAR-T therapies in clinical development
  • Increasing demand for innovative cancer treatments globally
  • Strategic partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly revenue of 174 million CNY, showing growth potential
  • Cash and short-term investments of 503 million CNY as of Q4 2025
  • Operating expenses reflect significant investment in research and development
JW (Cayman) Therapeutics Co. Ltd is positioned in a rapidly evolving biotechnology sector, focusing on innovative therapies that address significant unmet medical needs. The company's flagship product, Carteyva, is a promising CAR-T therapy that targets various blood cancers, while its expanding pipeline includes therapies for multiple myeloma and hepatocellular carcinoma. With a strong emphasis on research and development, the company aims to capitalize on the growing demand for advanced cancer treatments. Recent financial data indicates a solid cash position, allowing for continued investment in clinical trials and product development. The strategic focus on partnerships and innovative therapies positions JW (Cayman) Therapeutics as a noteworthy player in the biotechnology landscape.
AI Generated • Aug 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

314

CEO

Feng Tian

Website

www.jwtherapeutics.com

Headquarters

Shanghai, SH 200131, CN

JWCTF Financials

Key Financial Metrics (TTM)

Gross Margin

43.15%

Operating Margin

-105.50%

Net Income Margin

-196.12%

Return on Equity

-75.15%

Return on Capital

-29.51%

Return on Assets

-55.76%

Earnings Yield

-93.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$82.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

405.89M

Volume

680.00K

Avg. Volume

14.53K

Financials (TTM)

Gross Profit

CN¥198.44M

Operating Income

-CN¥296.13M

EBITDA

-CN¥609.67M

Operating Cash Flow

-CN¥369.75M

Capital Expenditure

-CN¥6.38M

Free Cash Flow

-CN¥376.13M

Cash & ST Invst.

CN¥503.32M

Total Debt

CN¥262.69M

Jw (Cayman) Therapeutics Performance Analysis

Jw (Cayman) Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 21,637,688353.1%
20232023-12-31CNY 24,538,50413.4%
20242024-12-31CNY 21,984,439-10.4%
20252025-12-31CNY 39,459,56079.5%
Jw (Cayman) Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-300.8%
Q42024-12-31-17.8%
Q22025-06-3048.9%
Q42025-12-3164.0%
Jw (Cayman) Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.3112.5%
20232023-12-31CNY -0.26-14.0%
20242024-12-31CNY -0.20-24.7%
20252025-12-31CNY -0.19-6.4%
Jw (Cayman) Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3038.3%
Q42024-12-31-44.8%
Q22025-06-3023.8%
Q42025-12-31-6.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥174.36M

+102.5%

Gross Profit

CN¥56.00M

+29.0%

Gross Margin

32.12%

N/A

Market Cap

$82.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$261.41K

N/A

Employees

314

N/A

Net Income

-CN¥283.24M

+26.9%

EBITDA

-CN¥138.52M

+38.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥503.32M

-50.2%

Total Debt

CN¥262.69M

-17.6%

Accounts Receivable

CN¥2.05M

N/A

Inventory

CN¥62.03M

+78.4%

Long Term Debt

CN¥36.26M

-81.7%

Short Term Debt

CN¥226.32M

+87.0%

Return on Assets

-55.76%

N/A

Return on Invested Capital

-49.96%

N/A

Free Cash Flow

-CN¥29.30M

+82.4%

Operating Cash Flow

-CN¥28.18M

+82.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NDTPNDT Pharmaceuticals Inc.
$0.51-6.16%
BXPHFBotanix Pharmaceuticals Limited
$0.02-25.33%
SCNLFScancell Holdings plc
$0.14+0.00%
MLLCFMolecular Partners AG
$3.80+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$142.98+1.27%
BITOProShares Trust - ProShares Bitcoin ETF
$9.29+0.06%
IBITiShares Bitcoin Trust
$38.98+0.07%
INTCIntel
$93.33-0.03%

Questions About JWCTF

What is the current price of Jw (Cayman) Therapeutics?

Jw (Cayman) Therapeutics is trading at $0.20 per share.

What is the 52-week range for Jw (Cayman) Therapeutics?

Over the past 52 weeks, Jw (Cayman) Therapeutics has traded between $0.20 and $0.66.

How much debt does Jw (Cayman) Therapeutics have?

As of the most recent reporting period, Jw (Cayman) Therapeutics reported total debt of CN¥37.57M.

How much cash does Jw (Cayman) Therapeutics have on hand?

Jw (Cayman) Therapeutics reported CN¥71.99M in cash and cash equivalents in its most recent financial results.

What is Jw (Cayman) Therapeutics’s dividend yield?

Jw (Cayman) Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services